Table 1. Patient and treatment characteristics.
| Variables | Number of patients (%) |
|---|---|
| Age (n = 160) (mean ± SD) | 60.8 ± 12.1 |
| Sex | |
| Male | 19 (11.9%) |
| Female | 141 (88.1%) |
| ECOG-PS | |
| 0–1 | 123 (76.9%) |
| 2 | 37 (23.1%) |
| Child-Pugh score | |
| Median (range) | 6 (5–10) |
| 5–6 | 109 (69.4%) |
| 7–9 | 45 (28.7%) |
| 10–15 | 3 (1.9%) |
| Missing | 3 (1.9%) |
| Underlying liver disease | |
| HBV infection | 75 (46.9%) |
| HCV infection | 39 (24.4%) |
| Tumor size (cm) | |
| Median (range) | 7.7 (1.0–24.5) |
| <10 cm | 94 (59.1%) |
| ≥10cm | 65 (40.9%) |
| Missing | 1 (0.6%) |
| Presence of tumor thrombus | |
| IVC | 20 (12.5%) |
| Portal vein | 156 (97.5%) |
| Site of PVTT | |
| Main or bilateral portal vein | 85 (54.5%) |
| Unilateral portal vein | 51 (32.7%) |
| Others | 20 (12.8%) |
| Missing | 4 (2.5%) |
| BCLC stage | |
| C | 157 (98.1%) |
| D | 3 (1.9%) |
| TNM stage (AJCC 8th) | |
| T stage | |
| T1a | 1 (0.6%) |
| T1b | 0 (0.0%) |
| T2 | 12 (7.5%) |
| T3 | 6 (3.8%) |
| T4 | 141 (88.1%) |
| N stage | |
| N0 | 142 (88.8%) |
| N1 | 18 (11.3%) |
| M stage | |
| M0 | 160 (100%) |
| Treatment timing | |
| 2009–2014 | 40 (25%) |
| 2015–2019 | 120 (75%) |
| Radiation technique | |
| 3D-CRT | 40 (25.0%) |
| IMRT/VMAT | 100 (62.5%) |
| SBRT | 20 (12.5%) |
| Fractionation | |
| Conventional | 23 (14.4%) |
| Hypofractionation | 117 (73.1%) |
| SBRT | 20 (12.5%) |
| BED (Gy10) | |
| Mean ± SD | 49.60 ± 18.63 |
| < 56 Gy10 | 98 (61.2%) |
| ≥ 56 Gy10 | 62 (38.8%) |
| GTV volume (cc) | |
| Median (range) | 309.0 (5.5–4774.0) |
| Previous treatment | |
| Surgery | 15 (9.4%) |
| TACE | 95 (59.4%) |
| Embolization | 4 (2.5%) |
| Chemotherapy | 5 (3.1%) |
| Sorafenib | 7 (4.4%) |
| MVA | 3 (1.9%) |
| RFA | 8 (5.0%) |
| Y-90 | 3 (1.9%) |
| Post RT treatment | |
| Surgery | 0 (0%) |
| TACE | 43 (26.9%) |
| Embolization | 2 (1.3%) |
| Chemotherapy | 5 (3.1%) |
| Sorafenib | 12 (7.5%) |
| MVA | 2 (1.3%) |
| RFA | 7 (4.4%) |
| Y-90 | 3 (1.9%) |
| Others | 5 (3.1%) |